Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | CO2 |
| Molecular Weight | 44.0095 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C=O
InChI
InChIKey=CURLTUGMZLYLDI-UHFFFAOYSA-N
InChI=1S/CO2/c2-1-3
| Molecular Formula | CO2 |
| Molecular Weight | 44.0095 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Carbon dioxide is a colorless gas occurring naturally in Earth's atmosphere. Carbon dioxide is a primary carbon source for life on Earth. It is produced by all aerobic organisms during metabolism of carbohydrates and lipids. Carbon dioxide is used in food industry as an acidity regulator and for production of carbonated soft drinks and soda water. In medicine, carbon dioxide is commonly used as an insufflation gas for minimally invasive surgery (laparoscopy, endoscopy, and arthroscopy) to enlarge and stabilize body cavities to provide better visibility of the surgical area. A mixture of carbon dioxide and oxygen is used for stimulation of breathing after apnea, in anesthetic procedures to increase the depth of respiration, to facilitate blind intubations in anesthetic practice.
CNS Activity
Sources: https://www.boconline.co.uk/internet.lg.lg.gbr/en/images/medical_carbon_dioxide410_56027.pdf?v=2.0
Curator's Comment: Carbon dioxide is naturally produced in all tissues.
Originator
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseCarbon dioxide is used to stimulate respiration after a period of apnoea |
|||
| Primary | Unknown Approved UseCarbon dioxide is used in chronic respiratory obstruction after it has been relieved |
|||
| Palliative | Unknown Approved UseCarbon dioxide is used to increase cerebral blood flow in arteriosclerotic patients undergoing surgery |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Characterisation of stationary phases in subcritical fluid chromatography with the solvation parameter model. III. Polar stationary phases. | 2006-03-31 |
|
| Potentiating effect of tramadol on methamphetamine-induced behavioral sensitization in mice. | 2006-03 |
|
| Differentiation of human bone marrow stem cells into cells with a neural phenotype: diverse effects of two specific treatments. | 2006-02-16 |
|
| Ultrafast transient absorption studies on photosystem I reaction centers from Chlamydomonas reinhardtii. 2: mutations near the P700 reaction center chlorophylls provide new insight into the nature of the primary electron donor. | 2006-01-15 |
|
| Pictet-Spengler reactions in multiphasic supercritical carbon dioxide/CO2-expanded liquid media. In situ generation of carbamates as a strategy for reactions of amines in supercritical carbon dioxide. | 2005-09-21 |
|
| Identification of 9,17-dioxo-1,2,3,4,10,19-hexanorandrostan-5-oic acid, 4-hydroxy-2-oxohexanoic acid, and 2-hydroxyhexa-2,4-dienoic acid and related enzymes involved in testosterone degradation in Comamonas testosteroni TA441. | 2005-09 |
|
| Optical-fiber-to-waveguide coupling using carbon-dioxide-laser-induced long-period fiber gratings. | 2005-08-15 |
|
| Isolation and characterization of a rhodococcus species strain able to grow on ortho- and para-xylene. | 2005-08 |
|
| Metabolism of the aliphatic nitramine 4-nitro-2,4-diazabutanal by Methylobacterium sp. strain JS178. | 2005-08 |
|
| Strong effects of an individual water molecule on the rate of light-driven charge separation in the Rhodobacter sphaeroides reaction center. | 2005-07-22 |
|
| Pathways and metabolites of microbial degradation of selected acidic pharmaceutical and their occurrence in municipal wastewater treated by a membrane bioreactor. | 2005-07 |
|
| Physico-chemical characteristics of Anopheles culicifacies and Anopheles varuna breeding water in a dry zone stream in Sri Lanka. | 2005-06 |
|
| Coupling aggressive mass removal with microbial reductive dechlorination for remediation of DNAPL source zones: a review and assessment. | 2005-04 |
|
| A1 reduction in intact cyanobacterial photosystem I particles studied by time-resolved step-scan Fourier transform infrared difference spectroscopy and isotope labeling. | 2005-02-15 |
|
| Laryngeal amyloidosis. | 2005-02 |
|
| Angiokeratoma circumscriptum naeviforme: successful treatment with carbon-dioxide laser vaporization. | 2005-02 |
|
| [Development of gastrotonometry and the future of its use in the monitoring of critically ill patients]. | 2005-01-23 |
|
| Low-concentration carbon dioxide is an effective adjunct to positive airway pressure in the treatment of refractory mixed central and obstructive sleep-disordered breathing. | 2005-01 |
|
| Anti-L-selectin antibody therapy does not worsen the postseptic course in a baboon model. | 2005 |
|
| Effects of the cortisol synthesis inhibitor metyrapone on the response to carbon dioxide challenge in panic disorder. | 2005 |
|
| Isolation and characterization of a novel sphingomonad capable of growth with chrysene as sole carbon and energy source. | 2004-12-15 |
|
| Antiangiogenic therapy with pioglitazone, rofecoxib, and trofosfamide in a patient with endemic kaposi sarcoma. | 2004-12 |
|
| Tretinoin treatment before carbon-dioxide laser resurfacing: a clinical and biochemical analysis. | 2004-12 |
|
| Meerwein-Ponndorf-Verley alkynylation of aldehydes: essential modification of aluminium alkoxides for rate acceleration and asymmetric synthesis. | 2004-11-21 |
|
| Role of tyrosine phosphorylation in sperm capacitation / acrosome reaction. | 2004-11-09 |
|
| Enzymatic reactions in anaerobic 2-methylnaphthalene degradation by the sulphate-reducing enrichment culture N 47. | 2004-11-01 |
|
| Photochemical preparation of highly functionalized 1-indanones. | 2004-10-29 |
|
| Metabolism of 2-mercaptobenzothiazole by Rhodococcus rhodochrous. | 2004-10 |
|
| Retention characteristics of porous graphitic carbon in subcritical fluid chromatography with carbon dioxide-methanol mobile phases. | 2004-09-03 |
|
| Difference between diabetic and nondiabetic smokers in the pituitary response to physical exercise. | 2004-09 |
|
| Supercritical carbon dioxide extraction of chamomile flowers: extraction efficiency, stability, and in-line inclusion of chamomile-carbon dioxide extract in beta-cyclodextrin. | 2004-08-18 |
|
| Anesthesiological hazards during laparoscopic transhiatal esophageal resection: a case control study of the laparoscopic-assisted vs the conventional approach. | 2004-08 |
|
| Influence of the organophosphorus insecticide phosphamidon on lentic water. | 2004-07 |
|
| Treatment of vitiligo by transplantation of cultured pure melanocyte suspension: analysis of 120 cases. | 2004-07 |
|
| Direct determination of carbon dioxide in aqueous solution using mid-infrared quantum cascade lasers. | 2004-06 |
|
| Hypoxia up-regulates triosephosphate isomerase expression via a HIF-dependent pathway. | 2004-05 |
|
| Energy cost and cardiorespiratory changes during the practice of Surya Namaskar. | 2004-04 |
|
| Use of CO2/O2 anesthesia in the collection of samples for serum corticosterone analysis from Fischer 344 rats. | 2004-03 |
|
| Supercritical carbon dioxide extraction of selected medicinal plants--effects of high pressure and added ethanol on yield of extracted substances. | 2004-02-26 |
|
| Dynamic co-evolution of peptides and chemical energetics, a gateway to the emergence of homochirality and the catalytic activity of peptides. | 2004-02 |
|
| FTIR difference spectroscopy in combination with isotope labeling for identification of the carbonyl modes of P700 and P700+ in photosystem I. | 2004-02 |
|
| Lack of difference in the rates of hypopigmentation with 90-microsecond pulsed and longer dwell time carbon-dioxide laser resurfacing. | 2004-02 |
|
| CO2, not HCO3-, facilitates oxidations by Cu,Zn superoxide dismutase plus H2O2. | 2004-01-20 |
|
| [Severe nephrotic syndrome in a young man taking anabolic steroid and creatine long term]. | 2003-12-07 |
|
| Identification of intramembrane hydrogen bonding between 13(1) keto group of bacteriochlorophyll and serine residue alpha27 in the LH2 light-harvesting complex. | 2003-10-17 |
|
| High-sensitivity photoacoustic leak testing. | 2003-10 |
|
| [Comparative estimation of effectiveness of nonsteroidal anti-inflammatory drugs used for postoperative pain management]. | 2003 |
|
| [Effectiveness of ketonal and diclofenac in spondylarthrosis complicated with spinal pain]. | 2003 |
|
| Crystal structure of NAD-dependent formate dehydrogenase. | 1992-06-01 |
|
| Oxidative degradation of phenanthrene by the ligninolytic fungus Phanerochaete chrysosporium. | 1992-06 |
Patents
Sample Use Guides
Carbon dioxide is usually administered through the lungs by inhalation. The major exceptions are when a metered supply is fed into the oxygenator of an extracorporeal circulation of a cardiopulmonary bypass system, and when the gas is used for laparoscopic surgery. As an additive to beverages, carbon dioxide is consumed orally.
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:04:25 GMT 2025
by
admin
on
Mon Mar 31 18:04:25 GMT 2025
|
| Record UNII |
142M471B3J
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Related Record | Type |
|---|
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
LOINC |
16551-4
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
13538-4
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
59165-1
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
28644-3
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
NDF-RT |
N0000180185
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
14640-7
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
51781-3
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
39465-0
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
77143-6
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
NDF-RT |
N0000010258
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
2021-4
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
2020-6
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
35685-7
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
13541-8
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
41647-9
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
2018-0
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
2028-9
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
39464-3
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
32306-3
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
JECFA EVALUATION |
INS-290
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
WHO-ATC |
A06AX02
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
19212-0
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
CFR |
21 CFR 862.1160
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
39466-8
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
CODEX ALIMENTARIUS (GSFA) |
INS-290
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
28645-0
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
57920-1
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
53089-9
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
34520-7
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
48391-7
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
2022-2
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
EPA PESTICIDE CODE |
16601
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
2027-1
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
13540-0
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
11557-6
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
38253-1
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
WHO-VATC |
QA06AX02
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
34728-6
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
14040-0
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
57922-7
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
FDA ORPHAN DRUG |
465114
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
57923-5
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
2026-3
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
20565-8
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
DSLD |
3848 (Number of products:1)
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
53458-6
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
57921-9
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
53090-7
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
2019-8
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
19223-7
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
CFR |
21 CFR 184.1240
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
2023-0
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
WHO-VATC |
QV03AN02
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
11211-0
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
LOINC |
14003-8
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
||
|
WHO-ATC |
V03AN02
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
4256
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
PRIMARY | |||
|
142M471B3J
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
PRIMARY | |||
|
100000076280
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
PRIMARY | |||
|
DB09157
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
PRIMARY | |||
|
124-38-9
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
PRIMARY | |||
|
DTXSID4027028
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
PRIMARY | |||
|
m3079
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
PRIMARY | Merck Index | ||
|
516
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
PRIMARY | |||
|
CHEMBL1231871
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
PRIMARY | |||
|
CARBON DIOXIDE
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
PRIMARY | |||
|
142M471B3J
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
PRIMARY | |||
|
280
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
PRIMARY | |||
|
D002245
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
PRIMARY | |||
|
C65288
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
PRIMARY | |||
|
2034
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB13243MIG
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
PRIMARY | |||
|
16526
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
PRIMARY | |||
|
204-696-9
Created by
admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
CARBON DIOXIDE (% Vol.)
Non-filtered cigarette(85 mm) Univ Kentucky- 9.4 Filtered cigarette(85 mm) New Yorl City- 9.6 Little cigars A(85 mm) Boston-8.5 Little cigars B (85 mm),New York City-13.2 Small cigars C(95 mm),New York City-12.7
|
||
|
|
SUB_CONCEPT->SUBSTANCE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> METABOLITE INACTIVE |
Unit: percent of total dose excreted (into Expired Air; 39.7% to 58.6%)
IN-VIVO
|
||
|
PARENT -> METABOLITE |
MAJOR
EXHALATION
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|